ABSTRACT:
Vitiligo is an acquired skin disorder of pigmentation in which the white patches are form on skin, with an incidence of 0.5% to 2% worldwide. Vitiligo is clinically characterised by the development of white patches on skin due to the loss of functioning melanocyte in the skin or hair. The main cause of Vitiligo involves the interaction between defects of natural and extrinsic melanocyte, immune innate to swelling and destruction of T-cell-mediated melanocyte. In modern medicine, the photo chemotherapy is satisfactory method for treatment of leucoderma, but it has very common adverse effect. In this review, we shall discuss the vitiligo treatments, causes and their important clinical and molecular aspects.
Cite this article:
Ravi Kumar, Sachin Tyagi. A Review on Natural Treatment’s of Vitiligo. Asian J. Pharm. Res. 2020; 10(4):263-267. doi: 10.5958/2231-5691.2020.00046.5
Cite(Electronic):
Ravi Kumar, Sachin Tyagi. A Review on Natural Treatment’s of Vitiligo. Asian J. Pharm. Res. 2020; 10(4):263-267. doi: 10.5958/2231-5691.2020.00046.5 Available on: https://asianjpr.com/AbstractView.aspx?PID=2020-10-4-4
REFERENCE:
1. Abu tahir M., Kumar P., Ansari S.H., Javed Ali. Current remedies for vitiligo, Autoimmunity Reviews 9 (2010) 516 –520.
2. Ghafourian E., Ghafourian S., Sadeghifard N., Mohebi R., Shokoohini Y. ezamoleslami, Hamat R.A. vitligo: Symptoms" Pathogenesisand Treatment, Int. J. Immunopathol. Pharmacol. (2014) vol. 27, P.485-489.
3. Dhvani M. Lakhani, Ashwini S. Deshpande, Various Treatments for Vitiligo: Problems Associated and Solutions, Journal of Applied Pharmaceutical Science, 2014Vol. 4 (11), pp. 101-105.
4. Tortora G.J., Derrickson B., Principles of Anatomy and physiology, Willey international, 11th edition, 2006; 150-151.
5. Faria A.R., Roberto G. Tarlé, G. Dellatorre, M.T. Mira, C.C., Castro S.D., Vitiligo - Part 2 - classification, histopathology and treatment, Anais Bras Dermatol. 2014; 89 (5): P-784-790.
6. What is Vitiligo, Fast Facts: An Easy-to-Read Series of Publications for the Public, U.S. Department of Health and Human Services, Public Health Service, November 2010.
7. British Associationof Dermatologists Patients Information Leaflets, August 2004.
8. Yoon J., Sun Y.W., Kim T.H., Complementary and Alternative Medicine for Vitiligo, Vitiligo– Management and Therapy, 2011, 143-158.
9. Kumar V., Abbas A.K., Fausto N., Robbins, Cortan. Pathologic Basis of Diseases, Elsevier, 7th edition, P-1230-1231.
10. Silva de Castro C.C.., do Nascimento L.M., Olandoski M., Mira M.T. A pattern of asso-2. ciation between clinical form of vitiligo and disease-related variables in a Brazilian population. J Dermatol Sci. 2012; 65:63-7.
11. Ezzedine K., Amazan E., Séneschal J., Follicular vitiligo: a new form of vitiligo. Pigment Cell Melanoma Res 2012; 25: 527–529.
12. Taïeb A, Picardo M, and the VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27–35.
13. Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009; 360: 160–69.
14. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC. Revised clas-1. Sification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012; 25: E1-13.
15. National Institute of Arthritis and Musculoskeletal and Skin Diseases. What is vitiligo? Fast facts: an easy-to-read series of publications for the public additional". Retrieved 2007.
16. Natural Vitiligo Treatment System.The Home Vitiligo Cure That Doctors Don't Want You to Discover,
17. Gawkrodger D.J., Ormerod A.D., Shaw L., Mauri-Sole I., Whitton M.E., Watts M.J., Anstey A.V., Ingham J., Young K. Guideline for the diagnosis and management of vitiligo. British Journal of Dermatology 2008, 159, pp1051–1076.
18. Talia K. Vitiligo in children: a review of classification, hypotheses of pathogenesis and treatment. World J Pediatric, 2009; (4):265-268.
19. Taieb A., vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Mel Res 25: 20119-13.
20. Koga M., Tango T., Clinical features and course of type A and type B vitiligo. Brit J Dermatol 118:223-228, 1988.
21. Moretti S., Vitiligo. Orphanet Encyclopedia. October 2003.
22. Arora A.K., Kumaran M.S. Pathogenesis of vitiligo: An update. Pigment Int 2017;4: P 65-77.
23. Spritz R.A. The genetics of generalized vitiligo: Autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med 2010; 19; 2:78.
24. Nath S.K., Majumder P.P., Nordlund J.J. Genetic epidemiology of vitiligo: Multilocus recessivity cross-validated. Am J Hum Genet 1994;55: P 981-990.
25. Zhang X.J., Chen J.J., Liu J.B. The genetic concept of vitiligo. J Dermatol Sci 2005; 39: P137-146.
26. Liu J.B., Li M., Chen H., Zhong S.Q., Yang S., Du W.D. Association of vitiligo with HLA-A2: A meta-analysis. J Eur Acad Dermatol Venereol 2007; 21:205-13.
27. Jin Y., Birlea S.A., Fain P.R., Ferrara T.M., Ben S., Riccardi S.L., Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 44 (2012): P 676– 680.
28. Alkhateeb A., Stetler G.L., Old W., Talbert J., Uhlhorn C., Taylor M., Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3–p32.2. Hum Mol Genet 2002; 11: P 661-667.
29. Traks T., Keermann M., Karelson M., Rätsep R., Reimann E., Silm H., Polymorphisms in Toll-like receptor genes are associated with vitiligo. Front Genet 2015; 6:278.
30. Šahmatova L., Tankov S., Prans E., Aab A., Hermann H., Reemann P., Micro RNA-155 is Dysregulated in the Skin of Patients with Vitiligo and Inhibits Melanogenesis-associated Genes in Melanocytes and Keratinocytes. Acta Derm Venereol 2016;96: P742-747.
31. LePoole I.C., vanden Wijngaard R.M., Westerhof W. Das P.K. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996; 148:1219-28.
32. Hegedus L., Heindenheim M., Gervil M. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol 74:120-123, 1994.
33. Ezzedine K., Eleftheriadou V., Whitton M., Geel N. V. Vitiligo, the lancet.com. January 15, 2015: 6736(14); 60763-60767.
34. Alkhateeb A., Fain P.R., Thody A., Bennett D.C., Spritz R. A. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16: 208–214.
35. Ezzedine K., Diallo A., Léauté-Labrèze C., Halo nevi association in nonsegmental vitiligo affects age at onset and depigmentation pattern. Arch Dermatol 2012; 148: 497–502.
36. Ongenae K., Geel N. V., Naeyaert J.M., Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 16:90-100, 2003.
37. Dwivedi M., Laddha NC., Arora P., Marfatia Y.S., Begum R., Decreased regulatory T-cells and CD4(+) /CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res 2013; 26: 586–951.
38. Wang X., Wang Q., Wu J., Jiang M., Chen L., Zhang C. Increased Expression of CXCR3 and its Ligands in Vitiligo Patients and CXCL10 as a Potential Clinical Marker for Vitiligo. Br J Dermatol 2016. 37.
39. Harris J.E., Harris T.H., Weninger W., Wherry E.J., Hunter C.A., Turka L.A. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol 132 (2012): 1869–1876.
40. Rashighi M., Harris J.E. Interfering with the IFN-gamma/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med 3 (2015): 343.
41. Dell’Anna M.L., Urbanelli S., Mastrofrancesco A., Camera E., Iacovelli P., Leone G. Alterations of mitochondria in peripheral blood mononuclear cells of vitiligo patients. Pigment Cell Res 2003; 16: 553-9.
42. Schallreuter K.U., Moore J., Wood J.M., Beazley W.D., Peters E.M., Marles L. K. Epidermal H2O2 accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: Identification of a general mechanism in regulation of all 6BH4-dependent processes? J Invest Dermatol 2001; 116:167-74.
43. Gibbons N.C., Wood J.M., Rokos H., Schallreuter K.U. Computer simulation of native epidermal enzyme structures in the presence and absence of hydrogen peroxide (H2O2): potential and pitfalls. J Invest Dermatol 126 (2006): 2576– 2582.
44. Gianfaldoni S., Wollina U., Tirant M., Tchernev G., Lotti J., Satolli F., Rovesti M., França K., Lotti T. Herbal Compounds for the Treatment of Vitiligo: A Review, Open Access Maced J Med Sci. 2018 Jan 25; 6(1):203-207.
45. Parsad D., Pandhi R., Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2003; 28(3):285-7.
46. Szczurko O., Shear N., Taddio A., Ginkgo biloba for the treatment of vitiligo vulgaris: an open label pilot clinical trial. BMC Complementary and Alternative Medicine. PMid: 21406109, 2011; 11:21.
47. Naini F.F., Shooshtari A.V., Ebrahimi B. The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: A pilot study. J Res Pharm Pract. 2012; 1(2):77-80.
48. Yuksel E.P., Aydin F., Senturk N. Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients. Eur J Dermatol. 2009; 19(4):341 -344.
49. Buggiani G., Tsampau D., Hercogovà J. Clinical efficacy of a novel topical formulation for vitiligo: compared evaluation of different treatment modalities in 149 patients. Dermatol Ther. 2012; 25(5):472-476.
50. Bedi K.L., Zutshi U., Chopra C.L. Picrorhiza kurroa, an ayurvedic herb, may potentiate photochemotherapy in vitiligo. J Ethnopharmacol. 1989; 27(3):347-52.
51. Ghafourian E. Ghafourian S. , Sadeghifard N. , Mohebi R. , Shokooittni Y., Nezamolledlami S. And Hamat R.A. Vitiligo: Symptoms" Pathogenesis and Treatments. International JIP. Vol. 27, no. 4, 485-489 (2014).
52. Anon. Vitiligo -treatment. Patient UK. NHS. Retrieved 2013-06-03.
53. Dhvani M. Lakhani, Ashwini S. Deshpande. Various Treatments for Vitiligo: Problems Associated and Solutions, Journal of Applied Pharmaceutical Science Vol. 4 (11), pp. 101-105, November, 2014.
54. Soni P., Patidar R., Soni V., Soni S., A Review on Traditional and Alteranative Treatment for Skin Disease “Vitiligo”, International Journal of Pharmaceutical and Biological Archives 2010; 1(3): 220 – 227.
55. Carlie G, Ntusi N.B., Hulley P.A. KUVA (khellin plus ultraviolet A) stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro. Br J Dermatol. 2003; 149(4):707-17.
56. Edlich R.F., Winters K.L., Lim H.W. Photoprotection by sunscreens with topical antioxidants and systemic antioxidants to reduce sun exposure. Journal of Long - Term effects of Medical Implants. 2004; 14: 317 - 340.
57. Berman B, Ellis C, Elmets C. Polypodium Leucotomos - An Overview of Basic Investigative Findings. J Drugs Dermatol. 2016; 15(2):224-8.
58. Nestor M., Bucay V., Callender V. Polypodium leucotomos as an Adjunct Treatment of Pigmentary Disorders. J Clin Aesthet Dermatol. 2014; 7(3):13-17.
59. Becatti M., Prignano F., Fiorillo C. The involvement of Smac/DIABLO, p53, NF - kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: Protective effects of curcumin and capsaicin. Antioxid Redox Signal. 2010; 13(9):130921.
60. Kwinter J., Pelletier J., Khambalia A., Pope E. High-potency steroid use in children 21. With vitiligo: a retrospective study. J Am Acad Dermatol. 2007; 56:236-241.
61. Lotti T, Berti S, Moretti S. Vitiligo therapy. Expert Opin Pharmacother.22. 2009; 10:2779-2785.
62. Falabella R., Barona M.I. Update on skin repigmentation therapies in vitiligo. Pigment24. Cell Melanoma Res. 2009; 22:42-65.